SEOM clinical guideline for the management of malignant melanoma (2017)

Berrocal, A. (Alfonso); Arance, A. (Ana); Castellon, V.E. (V. E.); Cruz, L. (L.) de la; Espinosa, E. (E.); Cao, M.G. (M. G.); Gonzalez-Larriba, J.L. (José Luis); Marquez-Rodas, I. (Iván); Soria, A. (Ainara); Martin-Algarra, S. (Salvador)

Keywords:

Melanoma
Metastatic
Adjuvant
Immunotherapy
B-RAF

Issue Date:

2018

Publisher:

Springer

ISSN:

1699-048X

Note:

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://crea tivecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Citation:

Berrocal, A. (A.); Arance, A. (Ana); Castellon, V.E. (V. E.); et al. "SEOM clinical guideline for the management of malignant melanoma (2017)". Clinical and translational oncology. 20 (1), 2018, 69 - 74

Abstract

All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.

URI:

https://hdl.handle.net/10171/65645

DOI:

10.1007/s12094-017-1768-1

Appears in Collections:

DA - CUN - Oncología médica - Artículos de revista

Files in This Item: